Department of HPB Surgery, Freeman Hospital, Newcastle-upon-Tyne, UK.
Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK.
Pancreatology. 2020 Apr;20(3):537-544. doi: 10.1016/j.pan.2020.01.004. Epub 2020 Jan 10.
Surgical resection remains the only curative treatment for pancreatic ductal adenocarcinoma (PDAC). The prognostic value of resection margin status following pancreatoduodenectomy (PD) remains controversial. Standardised pathological assessment increases positive margins but limited data is available on the significance of involved margins. We investigated the impact of resection margin status in PDAC on patient outcome.
We identified all patients with PD for PDAC at one pancreatic cancer centre between August 2008 and December 2014. Demographic, operative, adjuvant therapeutic and survival data was obtained. Pathology data including resection margin status of specific anatomic margins was collected and analysed.
107 patients were included, all pathologically staged as T3 with 102 N1. 87.9% of patients were R1 of which 53.3% showed direct extension to the resection margin. Median survival for R0 patients versus R1<1 mm and R1 = 0 mm was 28.4 versus 15.4 and 25.1 versus 13.4 months. R1 = 0 mm status remained a predictor of poor outcome on multivariate analysis. Evaluation of individual margins (R1<1 mm) showed the SMV and SMA margins were associated with poorer overall survival. Multiple involved margins impacted negatively on outcome. SMA margin patient outcome with R1 = 1-1.9 mm was similar to R1=>2 mm.
Using an R1 definition of <1 mm and standardised pathology we demonstrate that R1 rates in PDAC can approach 90%. R1 = 0 mm remained an independent prognostic factor for overall survival. Using R1<1 mm we have shown that involvement of medial margins and multiple margins has significant negative impact on overall survival. We conclude that not all margin positivity has the same prognostic significance.
手术切除仍然是治疗胰腺导管腺癌(PDAC)的唯一治愈方法。胰十二指肠切除术(PD)后切缘状态的预后价值仍存在争议。标准化的病理评估会增加阳性切缘的数量,但关于受累切缘的意义的数据有限。我们研究了 PDAC 患者 PD 切缘状态对患者预后的影响。
我们在一家胰腺癌中心确定了 2008 年 8 月至 2014 年 12 月期间所有接受 PD 治疗的 PDAC 患者。获取了人口统计学、手术、辅助治疗和生存数据。收集并分析了包括特定解剖切缘切缘状态在内的病理数据。
共纳入 107 例患者,所有患者的病理分期均为 T3,N1 为 102。87.9%的患者为 R1,其中 53.3%的患者直接侵犯切缘。R0 患者与 R1<1mm 和 R1=0mm 的中位生存期分别为 28.4 个月与 15.4 个月和 25.1 个月与 13.4 个月。多因素分析显示,R1=0mm 状态仍然是预后不良的预测因素。对单个切缘(R1<1mm)的评估显示,SMV 和 SMA 切缘与总体生存较差相关。多个受累切缘对预后有负面影响。SMA 切缘 R1=1-1.9mm 的患者的预后与 R1=>2mm 的患者相似。
使用 R1<1mm 的定义和标准化病理,我们证明 PDAC 中的 R1 率可接近 90%。R1=0mm 仍然是总生存的独立预后因素。使用 R1<1mm,我们已经表明,内侧切缘和多个切缘受累对总生存有显著的负面影响。我们得出结论,并非所有切缘阳性都具有相同的预后意义。